Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Progress in Neoantigen Targeted Cancer Immunotherapies.Frontiers in cell and developmental biology · 2020
   Review
2. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.Therapeutic advances in medical oncology · 2018
   Article

Corrections and comments

• Erratum for
  Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.2016

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.